Physician profile
Antony Charles
NPI 1467435222
$14,466.09
in general payments reported to CMS, 2019-2025
69 companies · $3,220 in 2025
The $3,220 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,516 · 2020: $1,096 · 2021: $1,060 · 2022: $1,868 · 2023: $2,095 · 2024: $2,610 · 2025: $3,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,609 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,608.76 |
| Education | $316.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $1,204.15 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Astrazeneca Pharmaceuticals LP | $1,070.09 | 2019-2025 | Lynparza, Tagrisso, Enhertu |
| Janssen Biotech, INC. | $852.97 | 2019-2025 | Darzalex, Talvey, Imbruvica |
| Merck Sharp & Dohme LLC | $764.42 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $748.74 | 2019-2025 | Opdivo, Opdualag |
| Pfizer INC. | $747.29 | 2019-2025 | |
| Seagen INC. | $630.94 | 2019-2023 | Padcev, Adcetris, Tukysa |
| Genentech USA, INC. | $571.46 | 2019-2025 | Polivy, Venclexta, Itovebi |
| Abbvie INC. | $526.15 | 2022-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $504.52 | 2019-2025 | |
| Eisai INC. | $502.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $477.69 | 2019-2025 | |
| Amgen INC. | $438.60 | 2019-2023 | Lumakras, Nplate, Vectibix |
| Daiichi Sankyo INC. | $408.36 | 2019-2025 | Enhertu, Vanflyta, Injectafer |
| Genzyme Corporation | $403.23 | 2019-2025 |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $360.70 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $342.63 | 2019-2025 | Ninlaro, Fruzaqla, Iclusig |
| Astellas Pharma US INC | $295.39 | 2019-2025 | Xtandi, Padcev |
| Exelixis INC. | $279.82 | 2019-2024 | Cabometyx |
| Glaxosmithkline, LLC. | $260.05 | 2020-2025 | Ojjaara, Blenrep, Zejula |
| Jazz Pharmaceuticals INC. | $249.16 | 2019-2024 | |
| Gilead Sciences, INC. | $238.19 | 2019-2025 | Trodelvy |
| Beigene USA, INC. | $213.43 | 2021-2025 | Brukinsa |
| Ipsen Biopharmaceuticals, INC | $174.02 | 2019-2024 | Tazverik |
| Lilly USA, LLC | $152.01 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $149.93 | 2019-2024 | Libtayo |
| Adaptive Biotechnologies Corporation | $105.14 | 2024-2025 | Clonoseq |
| Beone Medicines USA, INC. | $98.06 | 2025 | Brukinsa |
| Adc Therapeutics America, INC. | $97.78 | 2021-2025 | |
| Taiho Oncology, INC. | $94.16 | 2019-2022 | |
| Stemline Therapeutics INC. | $93.71 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $83.10 | 2019-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $79.15 | 2019-2023 | Imbruvica |
| Karyopharm Therapeutics INC. | $72.06 | 2020-2025 | Xpovio |
| Alexion Pharmaceuticals, INC. | $71.78 | 2019-2025 | Ultomiris |
| Caris Mpi, INC. | $70.56 | 2025 | Mi Cancer Seek |
| Sobi, INC | $70.21 | 2022-2024 | |
| Array Biopharma INC | $66.04 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Agios Pharmaceuticals, INC. | $61.75 | 2019-2024 | Pyrukynd |
| Pharmaessentia USA Corporation | $61.15 | 2025 | Besremi |
| Sanofi-Aventis U.S. LLC | $59.99 | 2019 | |
| Puma Biotechnology, INC. | $55.76 | 2022-2024 | |
| Coherus Oncology, INC. | $47.00 | 2021-2024 | |
| Kite Pharma, INC. | $42.31 | 2020-2025 | Yescarta |
| Morphosys, US INC. | $41.62 | 2023 | Monjuvi |
| Foundation Medicine, INC. | $41.27 | 2020-2022 | |
| Deciphera Pharmaceuticals INC. | $41.13 | 2024-2025 | Qinlock, Tgct |
| G1 Therapeutics, INC. | $34.41 | 2023 | Cosela |
| Tempus Ai, INC | $29.74 | 2025 | Xt Cdx |
| Recordati_rare_diseases_inc. | $28.35 | 2025 | Enjaymo |
| Verastem, INC. | $25.43 | 2019-2020 | |
| Secura Bio, INC. | $24.03 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $23.59 | 2022 | |
| Biocompatibles, INC. | $22.17 | 2019 | |
| Acceleron Pharma, INC. | $21.44 | 2021 | |
| Advanced Accelerator Applications | $21.30 | 2020 | |
| Pharmacosmos Therapeutics INC. | $20.97 | 2025 | Monoferric |
| Legend Biotech USA INC. | $19.82 | 2025 | Carvykti |
| Mirati Therapeutics, INC. | $19.73 | 2024 | Krazati |
| Boston Scientific Corporation | $19.73 | 2024 | Spaceoar Vue System - 10ml |
| Springworks Therapeutics, INC. | $19.45 | 2024 | Ogsiveo |
| Servier Pharmaceuticals LLC | $18.91 | 2024 | |
| Corcept Therapeutics | $18.50 | 2025 | Korlym |
| Cti Biopharma Corp. | $17.30 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $17.30 | 2022 | |
| Blueprint Medicines Corporation | $16.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.29 | 2019 | |
| Acrotech Biopharma INC. | $13.00 | 2023 | Beleodaq |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antony Charles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.